Simultaneous detection of pathogens in clinical samples from patients with community-acquired pneumonia by real-time

Miyuki Morozumi1, Eiichi Nakayama, Satoshi Iwata

  • 1Laboratory of Infectious Agents Surveillance, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.

Insights

This study developed a rapid real-time PCR assay using molecular beacons to detect six common community-acquired pneumonia (CAP) pathogens. The assay offers high sensitivity and specificity, aiding in timely diagnosis and treatment monitoring.

Area of Science:

  • Microbiology
  • Molecular Diagnostics
  • Infectious Diseases

Background:

  • Community-acquired pneumonia (CAP) poses a significant public health challenge.
  • Accurate and rapid identification of CAP causative agents is crucial for effective treatment.
  • Conventional diagnostic methods can be time-consuming, delaying appropriate therapy.

Purpose of the Study:

  • To evaluate a real-time PCR assay for simultaneous detection of six major CAP pathogens.
  • To assess the assay's performance in clinical specimens from pediatric and adult populations.
  • To determine the diagnostic accuracy (sensitivity and specificity) compared to conventional methods.

Main Methods:

  • Real-time PCR utilizing pathogen-specific molecular beacons (MB) and primers.
  • Detection of six key CAP agents: Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila, and Streptococcus pyogenes.
  • DNA extraction using EXTRAGEN II kit and amplification on Stratagene Mx3000P.

Main Results:

  • The assay achieved a limit of detection as low as 2 copies.
  • High sensitivity and specificity were observed for S. pneumoniae, H. influenzae, S. pyogenes, and M. pneumoniae compared to culture.
  • The entire process, from DNA extraction to analysis, was completed in under 2 hours.

Conclusions:

  • Real-time PCR with pathogen-specific MB is a rapid and effective tool for identifying CAP pathogens.
  • The assay supports timely clinical decision-making and monitoring of empirical chemotherapy.
  • This molecular method complements and enhances conventional diagnostic approaches for CAP.